Ipsen (IPSEY) announced confirmation of an expanded collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine tumors or pNETs and advanced extra-pancreatic neuroendocrine tumors or epNETs.
The agreement is based on positive outcomes from the CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute (NCI), which investigated Cabometyx versus placebo in people living with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy.
Ipsen noted that it has engaged with regulatory authorities in the European Union and will submit a regulatory filing on the basis of the data.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.